# SLC66A2

## Overview
SLC66A2 is a gene that encodes the protein solute carrier family 66 member 2, which is part of the solute carrier (SLC) family of transmembrane transporters. These proteins are integral to cellular processes, facilitating the transport of various molecules across cellular membranes. The SLC66A2 protein is implicated in the regulation of iron metabolism, which is crucial for numerous physiological functions and has been associated with various pathological conditions, including cancer. Research has highlighted its role in the tumor microenvironment and its potential impact on immune responses and treatment outcomes in cancer patients (Wang2022Clinical). Additionally, SLC66A2 has been studied in the context of pediatric B-cell acute lymphoblastic leukemia, where it may influence disease progression and treatment response (Li2024The). The gene's involvement in Alu exonization events further suggests its potential impact on gene function and disease pathogenesis (Florea2021Detection).

## Clinical Significance
The SLC66A2 gene, also known as PQLC1, has been implicated in various clinical contexts, particularly in cancer. In breast cancer, SLC66A2 is part of a seven-gene prognostic signature related to iron metabolism. This signature has been shown to predict clinical outcomes and responses to treatments, including immunotherapy. Patients with high expression levels of these genes, including SLC66A2, tend to have worse survival outcomes, suggesting its potential role in disease progression and treatment response (Wang2022Clinical). The gene's expression is associated with the tumor microenvironment, influencing immune and stromal scores, which are critical in cancer prognosis and therapy (Wang2022Clinical).

In pediatric B-cell acute lymphoblastic leukemia (B-ALL), SLC66A2 has been noted for its significant differences in fusion gene breakpoints before and after remission. This suggests a potential role in the disease's progression or response to treatment, highlighting its importance in understanding chemotherapy insensitivity (Li2024The).

Additionally, SLC66A2 has been identified as a locus for Alu exonization events in the human frontal cortex, which may impact gene function and contribute to disease pathogenesis (Florea2021Detection). These findings underscore the gene's potential clinical significance across different diseases.


## References


[1. (Li2024The) Xinyu Li, Zaoli Huang, Liwen Zhu, Weixin Lai, Yunyao Li, Han Chen, Diandian Liu, Junjiu Huang, Dunhua Zhou, Yang Li, Wenjun Weng, Honggui Xu, Luhong Xu, Zhenhua Luo, and Jianpei Fang. The potential role of rna sequencing in diagnosing unexplained insensitivity to conventional chemotherapy in pediatric patients with b-cell acute lymphoblastic leukemia. BMC Medical Genomics, May 2024. URL: http://dx.doi.org/10.1186/s12920-024-01892-w, doi:10.1186/s12920-024-01892-w. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12920-024-01892-w)

2. (Wang2022Clinical) Clinical implications and immunological features of iron metabolism-related gene prognostic signature in breast cancer. This article has 0 citations.

[3. (Florea2021Detection) Liliana Florea, Lindsay Payer, Corina Antonescu, Guangyu Yang, and Kathleen Burns. Detection of alu exonization events in human frontal cortex from rna-seq data. Frontiers in Molecular Biosciences, September 2021. URL: http://dx.doi.org/10.3389/fmolb.2021.727537, doi:10.3389/fmolb.2021.727537. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2021.727537)